News | EP Mapping and Imaging Systems | May 17, 2019

Acutus Medical Announces Rhythm Xience Acquisition, New Partnerships at HRS 2019

Partnership add access, therapy, diagnostics and rhythm monitoring solutions to Acutus’ portfolio

Acutus Medical Announces Rhythm Xience Acquisition, New Partnerships at HRS 2019

Acutus Medical's acquisition of Rhythm Xience brings the Flextra steerable introducer sheath into Acutus Medical's product portfolio.

May 17, 2019 — At the 40th annual Heart Rhythm Scientific Sessions, May 8-11 in San Francisco, Acutus Medical announced the agreement to acquire Rhythm Xience Inc., and new strategic partnerships with Peerbridge Health, Cardiac Designs and MedFact. Acutus' expanded portfolio builds on the organization's mapping and visualization technology platform.

The Rhythm Xience acquisition and partnership agreements create a foundation for Acutus to provide solutions spanning access, therapy, diagnostics and rhythm monitoring:

Access Sheaths and Introducers

Acutus is acquiring Rhythm Xience, known for its integrated family of novel and user-friendly transseptal crossing and steerable introducer systems. This acquisition expands Acutus' ability to improve access and effectively treat arrhythmias with: Flextra, a two-way steerable introducer sheath; Guider, a fixed curve introducer; and Lancer, a transseptal crossing device. All products are U.S. Food and Drug Administration (FDA)-cleared and commercially available.


To ensure early detection as well as to validate treatment efficacy, Acutus has partnered with Peerbridge Health to offer the advanced ambulatory Peerbridge Cor electrocardiogram (ECG). The Peerbridge system offers a truly wireless multi-channel ECG monitor that is FDA-cleared to detect up to 26 different arrhythmias. The system records every heartbeat for up to seven days and can transmit patient-activated events via the cloud, ensuring accelerated arrhythmia detection by clinical staff. At the end of each test, a quantitative analysis and atrial fibrillation (AFib) burden summary is delivered to prescribing physicians summarizing every cardiac event, both asymptomatic and patient-activated.

For longer-term remote monitoring, the Acutus QCheck handheld ECG and mobile app are now available through a partnership with Cardiac Designs. When individuals experience arrhythmia symptoms, QCheck records heart data and quickly displays results in the mobile app, which can then be transmitted to a medical professional via email or text. QCheck is available in the Apple App Store and Google Play by prescription or over the counter. All monitoring products are FDA-cleared and commercially available.

Robotic Ablation Catheters to Deliver Therapy Solutions

Acutus has signed an exclusive agreement with MedFact to distribute its robotically enabled point radiofrequency (RF) ablation catheter utilized for the Stereotaxis robotic navigation system. This agreement further enhances Acutus' integration with the Stereotaxis navigation system announced earlier this year.

The Acutus portfolio also includes its AcQMap advanced cardiac imaging and mapping system. AcQMap incorporates precision ultrasound atrial anatomy reconstruction and highly reproducible, high-definition non-contact charge density mapping. The system also provides workhorse contact mapping capabilities, now available in Europe. AcQMap's increased clarity of arrhythmia pattern mapping aids in the development of patient-specific ablation strategies. Unique to this system, physicians can rapidly remap and confirm the efficacy of each ablation.

For more information:

Related Content

Noninvasive Radioablation Offers Long-term Benefits to High-risk Heart Arrhythmia Patients
News | Ablation Systems | September 17, 2019
September 17, 2019 — Treating high-risk heart patients with a single, high dose of radiation therapy can dramatically
Biosense Webster Announces Initial Results From First-in-Human QDOT-FAST Study
News | Ablation Systems | May 16, 2019
Johnson & Johnson Medical Devices Companies announced that Biosense Webster, Inc.’s QDot Micro catheter...
CardioFocus Announces Results From HeartLight X3 Ablation System Pivotal Study
News | Ablation Systems | May 16, 2019
CardioFocus Inc. announced the presentation of results from its pivotal confirmatory study evaluating the HeartLight X3...
New Global Consensus Statement Addresses Catheter Ablation of Ventricular Arrhythmias
News | Ablation Systems | May 14, 2019
The Heart Rhythm Society (HRS) in partnership with three other professional societies issued an international consensus...
Netherlands Hospital to Install State-of-the-Art MRI Ablation Center
News | Ablation Systems | May 13, 2019
Imricor announced the signing of a commercial agreement with the Haga Hospital in The Hague, Netherlands to outfit a...
A CyberHeart cardiac ablation radiotherapy treatment plan showing where the radiation beam will ablate for a noninvasive pulmonary vein isolation procedure. Varian acquires, buys, purchases Cyberheart.

A CyberHeart cardiac ablation radiotherapy treatment plan showing where the radiation beams will ablate for a noninvasive pulmonary vein isolation procedure to treat an arrhythmia.

Feature | Ablation Systems | May 10, 2019 | Dave Fornell, Editor
May 10, 2019 — Radiation oncology vendor Varian announced it acquired the start-up company CyberHeart, which has deve
Ablation Reduces Risk of Dementia in Patients With AFib and Carotid Artery Disease
News | Ablation Systems | May 08, 2019
Even though many medical practitioners may opt not to perform procedures on higher-risk patients, new research finds it...
CardioFocus Announces European CE Mark Approval Of HeartLight X3 System
News | Ablation Systems | April 16, 2019
CardioFocus Inc. announced the European CE Mark approval of the HeartLight X3 Endoscopic Ablation System.
First Patient Treated With QDot Micro Ablation Catheter
News | Ablation Systems | February 04, 2019
Biosense Webster has enrolled and treated the first patient in its U.S. Investigational Device Exemption (IDE) study...
Overlay Init